Bio Atla, Inc. BCAB
We take great care to ensure that the data presented and summarized in this overview for BioAtla, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BCAB
View all-
Israel Englander Millennium Management LLC | New York, Ny2.66MShares$4.44 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.52MShares$4.2 Million0.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.89MShares$3.15 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.86MShares$3.1 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA874KShares$1.46 Million0.13% of portfolio
-
Black Rock Inc. New York, NY792KShares$1.32 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA686KShares$1.15 Million0.06% of portfolio
-
Bank Of Montreal Toronto, A6596KShares$994,8790.0% of portfolio
-
Massachusetts Financial Services CO Boston, MA569KShares$950,7840.0% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M525KShares$877,3390.0% of portfolio
Latest Institutional Activity in BCAB
Top Purchases
Top Sells
About BCAB
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Insider Transactions at BCAB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 31
2024
|
Eric Sievers Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
572
-0.27%
|
$572
$1.77 P/Share
|
|
Aug 31
2024
|
Scott Andrew Smith |
SELL
Payment of exercise price or tax liability
|
Direct |
2,181
-0.73%
|
$2,181
$1.77 P/Share
|
|
Jul 31
2024
|
Scott Andrew Smith |
SELL
Payment of exercise price or tax liability
|
Direct |
2,181
-0.72%
|
$2,181
$1.81 P/Share
|
|
Jul 31
2024
|
Eric Sievers Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
572
-0.27%
|
$572
$1.81 P/Share
|
|
Jun 30
2024
|
Scott Andrew Smith |
SELL
Payment of exercise price or tax liability
|
Direct |
2,181
-0.72%
|
$2,181
$1.37 P/Share
|
|
Jun 30
2024
|
Eric Sievers Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
572
-0.27%
|
$572
$1.37 P/Share
|
|
Jun 13
2024
|
Lawrence Steinman |
BUY
Grant, award, or other acquisition
|
Direct |
16,500
+23.09%
|
-
|
|
Jun 13
2024
|
Scott Andrew Smith |
BUY
Grant, award, or other acquisition
|
Direct |
16,500
+5.14%
|
-
|
|
Jun 13
2024
|
Sylvia Mcbrinn |
BUY
Grant, award, or other acquisition
|
Direct |
16,500
+31.65%
|
-
|
|
Jun 13
2024
|
Mary Ann Gray |
BUY
Grant, award, or other acquisition
|
Direct |
16,500
+23.44%
|
-
|
|
Jun 13
2024
|
Susan Moran |
BUY
Grant, award, or other acquisition
|
Direct |
16,500
+36.42%
|
-
|
|
Jun 13
2024
|
Eddie Williams |
BUY
Grant, award, or other acquisition
|
Direct |
16,500
+31.02%
|
-
|
|
May 31
2024
|
Scott Andrew Smith |
SELL
Payment of exercise price or tax liability
|
Direct |
2,181
-0.75%
|
$2,181
$1.51 P/Share
|
|
May 31
2024
|
Eric Sievers Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
572
-0.27%
|
$572
$1.51 P/Share
|
|
Apr 30
2024
|
Scott Andrew Smith |
SELL
Payment of exercise price or tax liability
|
Direct |
2,181
-0.75%
|
$4,362
$2.26 P/Share
|
|
Apr 30
2024
|
Eric Sievers Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
572
-0.27%
|
$1,144
$2.26 P/Share
|
|
Mar 31
2024
|
Eric Sievers Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
572
-0.27%
|
$1,716
$3.44 P/Share
|
|
Mar 31
2024
|
Scott Andrew Smith |
SELL
Payment of exercise price or tax liability
|
Direct |
2,181
-0.74%
|
$6,543
$3.44 P/Share
|
|
Feb 29
2024
|
Scott Andrew Smith |
SELL
Payment of exercise price or tax liability
|
Direct |
2,181
-0.73%
|
$4,362
$2.7 P/Share
|
|
Feb 29
2024
|
Eric Sievers Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
572
-0.27%
|
$1,144
$2.7 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 825K shares |
|---|---|
| Open market or private purchase | 81.5K shares |
| Payment of exercise price or tax liability | 24.5K shares |
|---|